Drugs / Personalized cancer vaccine (PCV)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07300475 | Oct 2026 → Jul 2030 expected | triple-negative breast carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized cancer vaccine (PCV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300475 ↗ |
| Modality | Vaccine | “personalized cancer vaccine (PCV)” NCT07300475 ↗ |
| Route | Intramuscular | “PCV is given intra-muscular (IM)” NCT07300475 ↗ |